Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U7 small nuclear 20 pseudogene (RNU7-20P) is a **pseudogene** corresponding to the U7 small nuclear RNA gene family[1][6]. Unlike functional U7 snRNA genes, which play a critical role in the 3' end processing of histone pre-mRNAs and are components of the U7 small nuclear ribonucleoprotein (snRNP) complex[3][4][5], RNU7-20P does not encode a functional RNA molecule and is not known to be transcribed or produce an active product[1][6]. Consequently, RNU7-20P does not participate in canonical cellular functions, is not regarded as a therapeutic or pharmacological target, and currently has no known association with disease, interacting drugs, or use as a biomarker[1][6]. **Clarifying issues**: RNU7-20P is a *pseudogene*, not an active gene or a classic drug target molecule such as a receptor, enzyme, transporter, or transcription factor. Pseudogenes are DNA sequences similar to functional genes but are usually nonfunctional due to mutations or lack of regulatory elements. The actual biologically active molecule in the U7 family is "RNA, U7 small nuclear" (RNU7), not its pseudogenes[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U7 small nuclear 20 pseudogene (RNU7-20P).